

---

**Product Data Sheet**

---

Product Name: KHK-IN-1 (ketoheokinase inhibitor)

Cat. No.: GC30367

**Chemical Properties**

Cas. No. 1303469-70-6

SMILES CSC(C=CC=C1)=C1NC2=NC(N3CCNCC3)=NC4=C2N=CN=C4NCC5CC5Formula  $C_{21}H_{26}N_8S$  M.Wt 422.55

Solubility Soluble in DMSO Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure **Protocol****Cell experiment****[1]:**

Cell lines NCI-N87 cells

Preparation Method NCI-N87 cells were cultured in RPMI1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% of penicillin/streptomycin at 37°C in the presence of 5% CO<sub>2</sub>. Cells were plated onto a 96-well plate at a density of  $1 \times 10^4$  cells/ml for 24h, and were treated with different concentrations of KHK-IN-1 hydrochloride (0, 1, 2, 3, 4, 5, and 6μM). After 4 days, cell viability was analyzed.

Reaction Conditions 0, 1, 2, 3, 4, 5, and 6μM; 4 days

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

**Product Data Sheet**

---

Applications KHK-IN-1 hydrochloride treatment significantly reduced the cell viability of NCI-N87 cells in a dose-dependent manner.

**Animal experiment [1]:**

Animal models Balb/c nude mice

Preparation Method Female Balb/c nude mice (5-week-old) were maintained under specific-pathogen-free (SPF) conditions. Five mice were held in each individually ventilated cage on a 12h/12h light/dark cycle with food and water ad libitum. The living status of mice was checked every day, and all the experiments were conducted after mice were housed for 7 days.  $1.5 \times 10^6$  NCI-N87 cells were injected subcutaneously into Balb/c nude mice. When the tumor masses grew to approximate  $50\text{mm}^3$ ,  $100\mu\text{l}$  KHK-IN-1 hydrochloride ( $50\mu\text{M}$ ) was peritumorally injected every day. The treatment duration was 14 days. The sizes of the tumor masses and the body weights of mice were measured every day.

Dosage form  $50\mu\text{M}$  ( $100\mu\text{l}$ ); once a day for 14 days; peritumoral injection

Applications KHK-IN-1 hydrochloride treatment inhibited tumor growth in the NCI-N87-xenograft mouse models, without affecting the body weight.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

### References:

[1] Ma G, Liu S, Cai F, et al. Ketoheokinase-A deficiency attenuates the proliferation via reducing  $\beta$ -catenin in gastric cancer cells[J]. Experimental Cell Research, 2024, 438(1): 114038.

### Background

KHK-IN-1 (ketoheokinase inhibitor) is a selective and cell membrane-permeable ketoheokinase (KHK) inhibitor with an  $IC_{50}$  value of 12nM [1]. KHK-IN-1 hydrochloride inhibits the activity of KHK by docking within the ATP-binding pocket of KHK, with a good solubility[2]. KHK-IN-1 hydrochloride has been widely used to inhibit the *C. auris* strain 0390 and prevent the formation of biofilms[3].

In vitro, KHK-IN-1 hydrochloride treatment for 4 days significantly inhibited the proliferation of NCI-N87 and HGC-27 cells, with  $IC_{50}$  values of 3.66 $\mu$ M and 2.31 $\mu$ M, respectively[4].

In vivo, KHK-IN-1 hydrochloride treatment via daily peritumoral injection of 100 $\mu$ l (50 $\mu$ M) for 14 days significantly inhibited tumor growth in the NCI-N87-xenograft mouse models, without affecting the body weight of the mice[4].

### References:

[1] Maryanoff B E, O'Neill J C, McComsey D F, et al. Pyrimidinopyrimidine inhibitors of ketoheokinase: exploring the ring C2 group that interacts with Asp-27B in the ligand binding pocket[J]. Bioorganic & medicinal chemistry letters, 2012, 22(16): 5326-5329.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

- [2] Maryanoff B E, O'Neill J C, McComsey D F, et al. Inhibitors of ketohexokinase: discovery of pyrimidinopyrimidines with specific substitution that complements the ATP-binding site[J]. ACS medicinal chemistry letters, 2011, 2(7): 538-543.
- [3] Ajetunmobi O H, Wall G, Vidal Bonifacio B, et al. High-throughput screening of the repurposing hub library to identify drugs with novel inhibitory activity against *Candida albicans* and *Candida auris* biofilms[J]. Journal of Fungi, 2023, 9(9): 879.
- [4] Ma G, Liu S, Cai F, et al. Ketohexokinase-A deficiency attenuates the proliferation via reducing  $\beta$ -catenin in gastric cancer cells[J]. Experimental Cell Research, 2024, 438(1): 114038.

**Caution: Product has not been fully validated for medical applications. For research use only.**

**Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com**

**Address: 10292 Central Ave. #205, Montclair, CA, USA**